SynthesisClinical and molecular hepatology2024
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Synthesis in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- [Meta analysis of the prevalence and risk factors of non-alcoholic fatty liver disease in overweight and obese children and adolescents in China].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Pooled it
- Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.Hepatology communications · 2026Trial
- Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies.International journal of pharmaceutics: X · 2026Review
- Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Article
- Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.Nature reviews. Gastroenterology & hepatology · 2026Review
- Associations of General and Central Obesity with Cardiovascular Risk by Menopausal and MASLD Status.Biomedicines · 2026Article
- Differentiating hepatic hemangiomas from hepatocellular carcinomas using Sonazoid-enhanced ultrasonography: a proposed two-step diagnostic algorithm.Ultrasonography (Seoul, Korea) · 2026Article
- Life's crucial 9, plasma proteomics, and the risk of major complications and mortality in MASLD.npj metabolic health and disease · 2026Article
- Association of M2BPGi with Subclinical Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".Clinical and molecular hepatology · 2026Article
- Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease.The journal of nutrition, health & aging · 2026Article
- Hypertension Associated with the Risk of Extrahepatic Cancers in the Metabolic Dysfunction-associated Steatotic Liver Disease Population: A Multicenter Cross-sectional Study in China.Journal of clinical and translational hepatology · 2026Article
- Liver function indicators as risk factors of pediatric metabolic (dysfunction)-associated fatty liver disease: a systematic review and meta-analysis.Translational pediatrics · 2026Article
- Impact of household air pollution on under 5 mortalities and ARI in sub saharan africa: evidence from demographic and health survey 2010-2020.Scientific reports · 2026Article
- Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease.Journal of advanced research · 2026Article
- Incidence of Chronic Kidney Disease According to Steatotic Liver Disease and Its Subclassifications: A Longitudinal Cohort Study.Gut and liver · 2026Article
- Article
- Association between UMAP-identified body composition phenotypes and metabolic dysfunction-associated steatotic liver disease in the general population of China.Frontiers in nutrition · 2026Article
- Metabolic dysfunction-associated fatty liver disease increases the risk of new-onset type 2 diabetes mellitus: a retrospective cohort study based on health check-up data.Frontiers in medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsNonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events.
methodsWe performed a systematic review and meta-analysis of cohort studies of adults with NAFLD to evaluate the pooled incidence of adverse events.
results19,406 articles were screened, 409 full-text articles reviewed, and 79 eligible studies (1,377,466 persons) were included. Mean age was 51.47 years and body mass index 28.90 kg/m2. Baseline comorbidities included metabolic syndrome (41.73%), cardiovascular disease (CVD) (16.83%), cirrhosis (21.97%), and nonalcoholic steatohepatitis (NASH) (58.85%). Incidence rate per 1,000 person-years for mortality included: all-cause (14.6), CVD-related (4.53), non-liver cancer-related (4.53), and liver-related (3.10). Incidence for liver-related events included overall (24.3), fibrosis progression (49.0), cirrhosis (10.9), liver transplant (12.0), and hepatocellular carcinoma (HCC) (3.39). Incidence for non-liver events included metabolic syndrome (25.4), hypertension (25.8), dyslipidemia (26.4), diabetes (19.0), CVD (24.77), renal impairment (30.3), depression/anxiety (29.1), and non-liver cancer (10.5). Biopsy-proven NASH had higher incidence of HCC (P=0.043) compared to non-NASH. Higher rates of CVD and mortality were observed in North America and Europe, hypertension and non-liver cancer in North America, and HCC in Western Pacific/Southeast Asia (P<0.05). No significant differences were observed by sex. Time-period analyses showed decreasing rates of cardiovascular and non-liver cancer mortality and increasing rates of decompensated cirrhosis (P<0.05).
conclusionPeople with NAFLD have high incidence of liver and non-liver adverse clinical events, varying by NASH, geographic region, and time-period, but not sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.